Ixaka
An integrated cell and gene therapy company focused on the natural power of the body to cure disease
An integrated cell and gene therapy company focused on the natural power of the body to cure disease
Ixaka is an integrated cell and gene therapy company focused on leveraging the body's natural power to cure diseases. Founded in 2015, Ixaka, formerly known as Rexgenero, operates in the UK, Spain, and France. The company's proprietary technologies aim to enhance the therapeutic power of cells by targeting curative cells to disease sites and directly modifying cells within the body to improve their therapeutic action.
Ixaka's technologies, including concentrated multi-cell therapies and targeted nano-particles, show potential for treating a wide array of serious diseases across fields such as oncology, cardiovascular, neurological, ocular diseases, and genetic disorders. With its headquarters in the United Kingdom, Ixaka has offices in London, and its R&D and manufacturing operations are located in Seville, Spain, and Paris, France, with additional manufacturing capability in Frankfurt, Germany.
The company recently secured a $54.00M Venture Round investment on 19 January 2021 from ZenPharma Limited. Ixaka operates in the Biotechnology, Health Care, and Health and Wellness industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $54.00M | 1 |
|
19 Jan 2021 |
| Grant | £267.00K | 1 |
|
21 Aug 2019 |
| Grant | £1.40M | 1 |
|
23 Jan 2018 |
| Series A | €13.10M | 1 |
|
26 Jan 2016 |
| Seed Round | €1.90M | 1 |
|
12 Jun 2015 |
No recent news or press coverage available for Ixaka.
We care about your data, and we'd love to use cookies make your experience better.
